» Articles » PMID: 15070571

Migraine

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2004 Apr 9
PMID 15070571
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

Migraine is a very common neurobiological headache disorder that is caused by increased excitability of the CNS. It ranks among the world's most disabling medical illnesses. Diagnosis is based on the headache's characteristics and associated symptoms. The economic and societal effect of migraine is substantial: it affects patients' quality of life and impairs work, social activities, and family life. There are many acute and preventive migraine treatments. Acute treatment is either specific (triptans and ergots) or non-specific (analgesics). Disabling migraine should be treated with triptans. Increased headache frequency is an indication for preventive treatment. Preventive treatment decreases migraine frequency and improves quality of life. More treatments are being developed, which provides hope to the many patients whose migraines remain uncontrolled.

Citing Articles

The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature.

Zhu Z, Tang Y, Li L, Ni H, Liu M, Chen Z J Headache Pain. 2025; 26(1):48.

PMID: 40065213 PMC: 11892237. DOI: 10.1186/s10194-025-01984-7.


Exploring vestibulocerebellum-vestibular nuclei-spinal trigeminal nucleus causals communication and TRPV2 ion channel in a mouse model of vestibular migraine.

Zhai Q, Chen Q, Zhang N, Li H, Yu Q, Pan Y J Headache Pain. 2025; 26(1):47.

PMID: 40045241 PMC: 11881311. DOI: 10.1186/s10194-025-01986-5.


Exploring the role of ubiquitination modifications in migraine headaches.

Zhu Q, Yang J, Shi L, Zhang J, Zhang P, Li J Front Immunol. 2025; 16:1534389.

PMID: 39958329 PMC: 11825825. DOI: 10.3389/fimmu.2025.1534389.


Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database.

Lu W, Wang S, Tang H, Yuan T, Zuo W, Liu Y Eur Psychiatry. 2025; 68(1):e20.

PMID: 39901452 PMC: 11823005. DOI: 10.1192/j.eurpsy.2024.1803.


Understanding Deep Endometriosis: From Molecular to Neuropsychiatry Dimension.

Pszczolowska M, Walczak K, Kolodziejczyk W, Kozlowska M, Kozlowski G, Gachowska M Int J Mol Sci. 2025; 26(2).

PMID: 39859551 PMC: 11765589. DOI: 10.3390/ijms26020839.